
|Articles|August 18, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Future Immune Checkpoint Strategies
Author(s)James P. Allison, PhD
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Advertisement
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Learn about the history of immunotherapy > >
Articles in this issue
over 11 years ago
A Brief History of Immunotherapyover 11 years ago
Better Biomarker Testing Needed in Immuno-Oncologyover 11 years ago
Autoimmunity and Limitations of Cancer Vaccinesover 11 years ago
The Management of Side Effects Associated With Immunotherapiesover 11 years ago
The Next Wave in Immunotherapy: CombinationsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















